DALLAS, TX / ACCESSWIRE / December 27, 2017 / Regarding lower spine and nerve issues, seldom are any as debilitating and problematic than the symptoms caused by sciatica, says Dallas Spine and Disc Center founder Dr. Karl Jawhari, D.C. As an experienced and renowned chiropractor, he has treated countless patients who are dealing with the acute pain and numbness from the condition. Dr. Jawhari possesses a deep understanding of both the underlying causes of sciatica and the many effective, non-invasive methods that can either ease or completely remove the discomfort for those suffering from it.

“While the term ‘sciatica’ may sound like it refers to a specific issue, it can include a number of different problems all stemming from a root cause,” Dr. Jawhari explains. It is essentially a set of symptoms, including pain, all caused by general compression or irritation involving one of five spinal nerve roots, or irritation of the left, right, or both sciatic nerves. Those that experience sciatica often notice a burning sensation, numbness, or a tingling that radiates from the lower back and upper buttocks, and further down the back of the affected thigh and leg. This can often make simple activities such as walking extremely painful. Although there are several possible underlying causes, the most common ones involve a herniated disk, a bone spur in the spine, or the narrowing of the spine that compresses part of a nerve. These instances can come as a result of injury, osteoporosis, stress, strenuous activity, and even pregnancy.

When addressing sciatica, an all-encompassing approach is the most effective. Due to the different levels of severity, it’s important to first pinpoint where the problem is originating from. “X-rays and other tests such as CT scan, MRI scan, and electromyogram can be used to further define the exact causes,” says Dr. Karl Jawhari. “The image and resolution produced by the MRI is quite detailed, and can detect even the smallest changes of structures within the body.” After identifying the origin of the sciatica, a specific treatment plan can be developed. Although many are tempted to rely on prescription painkillers and simply wait for the pain to subside over several weeks after a diagnosis, a recent study by the New England Journal of Medicine concluded that this “does not reduce the intensity of leg pain associated with sciatica.” Dr. Jawhari instead recommends undergoing chiropractic adjustments in both the pelvic and lower back areas to alleviate pain and numbness, engaging in light physical activity if possible, and reducing stress levels.

Dr. Karl Jawhari is a back pain expert and the founder of Dallas Spine and Disc Center. A graduate of both South Florida and Life University, Dr. Jawhari is a certified Health Coach by the U.S. Wellness Chamber of Commerce and educates people on how to achieve better health and lasting pain relief, regardless of age and body types. In addition to being a practicing Doctor of Chiropractic, he is the author of the book “Why Hormones Are Making You Fat” and offered expertise as a consultant to over 120 physicians in the United States. Dr. Jawhari is also a national speaker with the Health Awareness Foundation, a non-profit organization that promotes health and wellness in local businesses and communities by conducting educational workshops.

Dr. Karl Jawhari, D.C. – Founder of Dallas Spine and Disc Center: http://www.DrKarlJawhariNews.com
Dr. Karl Jawhari – LinkedIn: https://www.linkedin.com/in/dr-karl-jawhari-1b84b516
Karl Jawhari (@DrKarlJawhari) – Twitter: https://twitter.com/drkarljawhari

Contact Information:

DrKarlJawhariNews.com
http://drkarljawharinews.com
contact@drkarljawharinews.com

SOURCE: Dr. Karl Jawhari

ReleaseID: 484992

NEW YORK, NY / ACCESSWIRE / December 27, 2017 / Bill Lerner expanded aggressively while simultaneously redeveloping and completely modernizing his business’ operational functions when he took over as President and CEO of Imperial Parking Systems in 1997. Twenty years later, and with a new name for a digital era, Lerner has grown iPark into the largest and most technologically advanced privately owned parking garage operator in New York, with nearly 150 facilities. The company’s newly gained prominence has allowed for recent partnerships with Tesla Motors, Inc. and Beam Charging, a subsidiary of CarCharging, which have led to the installation of charging stations for hybrid and electric vehicles in over 25 garages, cementing iPark as a pioneer of eco-friendly parking.

“In 2014, the United States imported about 27% of the petroleum it consumed, and transportation was responsible for nearly three-quarters of total consumption. With much of the world’s petroleum reserves located in politically volatile countries, the United States is constantly vulnerable to price spikes and supply disruptions,” as reported by Alternative Fuels Data Center. Hybrid (HEVs) and plug-in electric vehicles (EVs) can help increase energy security, improve fuel economy, lower fuel costs, and reduce harmful emissions. These vehicles are capable of using off-board sources of electricity, produced in the U.S. almost strictly from domestic coal, nuclear energy, natural gas, and renewable resources, noted Bill Lerner. In addition, these cars produce zero tailpipe emissions when in all-electric mode.

The next generation fast EV charging stations installed in iPark garages utilize recently patented split rotor generators combined with a 120 horsepower natural gas engine for a green, grid-free charge, Lerner explained. The iPark app will conveniently guide people to the facilities equipped with these stations. Differing from current services that require 360 to 480 three-phase grid power, the next gen fast EV stations create their own electrical power internally, using a quite engine to drive the unique generator, allowing them to always be available, regardless of the status of the grid. With prices per charge as much as 60% lower than traditional charging stations, these advancements allow for a lower cost to both the consumer and the surrounding environment.

Bill Lerner is an American businessman and philanthropist best known for his successes as the CEO of iPark and for the work of his charity, Billy4Kids. Founded by Lerner’s father over 60 years ago, iPark began as a single 25-car lot for veterans returning to work in the city, known then as Imperial Parking Systems. Since Bill Lerner took over as President & CEO in 1997, the company has expanded to nearly 150 facilities and is currently the largest family-owned parking garage operator in New York. In 2013, he co-founded Billy4Kids, a non-profit that provides shoes for under-resourced children in developing countries. With over 4,000 pairs of shoes delivered to date, Lerner’s work has earned him the Humanitarian Award at the annual Edeyo Gives Hope Gala, and recognition from St. Mary’s Healthcare System for Children for three consecutive years.

Bill Lerner – President and CEO of iPark: http://billlernernews.com
Billy Lerner (@billy_lerner) – Twitter: https://twitter.com/billy_lerner
Billy Lerner – Home – Facebook: https://www.facebook.com/billylernerofficial/

Contact Information:

BillLernerNews.com
http://billlernernews.com
contact@billlernernews.com

SOURCE: Bill Lerner

ReleaseID: 484991

NEW YORK, NY / ACCESSWIRE / December 27, 2017 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Acorda Therapeutics, Inc. (“Acorda” or the “Company”) (NASDAQ: ACOR) of the January 16, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Acorda stock or options between April 18, 2016 and November 14, 2017 and would like to discuss your legal rights, click here: www.faruqilaw.com/ACOR. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

The lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all those who purchased Acorda securities April 18, 2016 and November 14, 2017 (the “Class Period”). The case, Hague v. Acorda Therapeutics, Inc. et al, No. 17-cv-08997 was filed on November 17, 2017.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by misrepresenting the benefits of the acquisition of Biotie Therapies Corporation (“Biotie”), specifically when referring to the tozadenant’s approval prospects and commercial viability.

On January 19, 2016, Acorda announced the acquisition of Biotie for approximately $363 million, touting to investors that the Company would obtain worldwide right to tozadenant, a trial Parkinson’s disease treatment that was then undergoing Phase 3 development. The Company further disclosed to have acquired approximately 93% of the fully diluted capital stock on April 18, 2016, and had finalized the acquisition by September 2016. During the relevant Class Period, the Company made misleading statements regarding the safety risks of tozadenant.

On November 15 2017, Acorda announced that it had identified seven cases of sepsis in patients, five of which were fatal, during the final-stage trial studies of tozadenant. The Company also announced that new patient enrollment in the trial would be stopped.

After the announcement, Acorda’s share price fell from $28.20 per share on November 14, 2017 to a closing price of $17 on November 15, 2017 – an $11.20 or a 39.72% drop.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Acorda’s conduct to contact the firm, including whistleblowers, former employees, shareholders, and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

CONTACT:

FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

SOURCE: Faruqi & Faruqi, LLP

ReleaseID: 484989

NEW YORK, NY / ACCESSWIRE / December 27, 2017 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Endo International, Plc. (“Endo International” or the “Company”) (NASDAQ: ENDP) of the January 16, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Endo International stock or options between September 28, 2015 and February 28, 2017 and would like to discuss your legal rights, click here: www.faruqilaw.com/ENDP. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

The lawsuit has been filed in the U.S. District Court for the Eastern District of Pennsylvania on behalf of all those who purchased Endo International securities between September 28, 2015 and February 28, 2017 (the “Class Period”). The case, Pelletier v. Endo International, Plc., No 2:17-cv-05114 was filed on November 14, 2017.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) Par Pharmaceutical had colluded with several of its industry peers to fix generic drug prices; (ii) the conduct constituted a violation of federal antitrust laws; (iii) the competitive advantages of the Par Pharmaceutical Acquisition were derived in part from Par Pharmaceutical’s illegal conduct; (iv) for the same reasons, the “impressive track record of delivering strong operating results” that Endo attributed to Campanelli in announcing his promotion to Endo’s CEO consisted in part of illegal conduct; (v) for the foregoing reasons, Endo’s revenues during the Class Period were in part the result of illegal conduct and likewise unsustainable; and (vi) as a result of the foregoing, Endo’s public statements were materially false and misleading at all relevant times.

Specifically, on November 3, 2016, media outlets reported that U.S. prosecutors were considering filing criminal charges by the end of 2016 against Par Pharmaceutical and several other pharmaceutical companies for unlawfully colluding to fix generic drug prices.

Then, on March 1, 2017, Endo filed an Annual Report on Form 10-K with the SEC, reporting in full the Company’s financial and operating results for the quarter and year ended December 31, 2016. Reflecting the extent to which Par Pharmaceutical’s unlawful conduct had previously inflated Endo’s revenues.

After the announcements, Endo International’s share price fell significantly.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Endo International’s conduct to contact the firm, including whistleblowers, former employees, shareholders, and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

CONTACT:

FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

SOURCE: Faruqi & Faruqi, LLP

ReleaseID: 484988

NEW YORK, NY / ACCESSWIRE / December 27, 2017 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Omega Healthcare Investors, Inc. (“Omega” or the “Company”) (NYSE: OHI) of the January 16, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Omega stock or options between February 8, 2017, and October 31, 2017 and would like to discuss your legal rights, click here: www.faruqilaw.com/OHI. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

The lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all those who purchased Omega securities between February 8, 2017, and October 31, 2017 (the “Class Period”). The case, Gronich v. Omega Healthcare Investors, Inc. et al, No. 1:17-cv-08983 was filed on November 16, 2017.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose that: (1) financial and operating results of certain of the Company’s operators were deteriorating; (2) certain of the Company’s operators were experiencing worsening liquidity issues that were significantly impacting the operators’ ability to make timely rent payments; and (3) as a result, certain of the Company’s direct financing leases were impaired and certain receivables were uncollectible.

Specifically, on July 26, 2017, the Company reported its second quarter 2017 financial results. During a conference call held the next day by the Company, Chief Operating Officer Daniel Booth stated that the Company continued “to see certain regional operators struggle with various operational pressures” and that two of the Company’s top ten private operators had seen margins and coverages decline, which created liquidity concerns.

On this news, the Company’s share price declined from $33.45 on July 26, 2017, to $32.10 on July 27, 2017 – a $1.35 or a 4.04% drop.

Then, on October 30, 2017, Omega announced its third quarter 2017 financial results. The next day, the Company held a conference call to discuss its results, wherein Daniel Booth disclosed that the Company “[continued] to experience specific operator performance issues” in addition to issues with Signature Healthcare, due to “liquidity issues [that] are impacting the ability of these operators to pay rent on a timely basis.” During the same call, Robert Stephenson, the Company’s Chief Financial Officer, stated that the Company’s decrease in operating revenue “was primarily a result of placing Orianna on a cash basis.”

Following the announcement, Omega’s share price fell from $30.97 per share on October 30, 2017 to a closing price of $28.86 on October 31, 2017 – a $2.11 or a 6.81% drop.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Omega’s conduct to contact the firm, including whistleblowers, former employees, shareholders, and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

CONTACT:

FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

SOURCE: Faruqi & Faruqi, LLP

ReleaseID: 484987

KOWLOON, HONG KONG / ACCESSWIRE / December 27, 2017 / Mr. William Ko, President, president of LOTUS BIO-TECHNOLOGY DEVELOPMENT CORP. (OTC PINK: LBTD) is excited to announce the company’s intelligent mining strategy for digital currency. It has obtained its first shipment of servers for inspection and testing.

Follow us on our twitter feed for updates @lbtd_coin_rig

The current combined market cap of all cryptocurrencies is valued at $597,764,502,262, up from $557,000,000,000 the previous trading session. See https://coinmarketcap.com for more information.

CPU and GPU flip speed is very important to computation speed. Algorithms are mathematical equations that are calculated with GPU and CPU and co-processors. The faster the GPU and CPUs, the faster the computation.

HASH rate is the number of calculations that your hardware can perform every second as it tries to crack the mathematical problem which ties in with CPU and GPU. The highest HASH rates are from AntMiner S9 (https://en.bitcoin.it/wiki/Mining_hardware_comparison).

Hard drive speed is optimized using flash memory. SLC (single layered cell) are faster than MMC and faster than TLC. Our servers use SLC.

NOR architecture and NAND gates architecture will be used on our rigs to optimize those that require ultra-fast speed writes to memory and displace slow jobs to NAND gates.

The staff from COIN Rig Solutions will lead our mining efforts. They will bring the highest COIN mining hash rates with their programming.

“As a topic of discussion and debate, we are experiencing a revitalization of seeking the highest clock speeds. Intel has given us moderate clock speeds with multiple cores (threads). It serves the needs of many multi-threaded applications but is slow and is bound by concurrency deadlocks. We are experiencing the ‘clock speed’ revolution as we had back in the 1990s where we experimented with cooling, multiplying bus rates, Cyrix, AMD, Intel chips and MMX DX and AGP processors. This is very nostalgic. But in general, the cloud and VMs have been in a mode complacency of moderate clock speeds. We believe in AMD high clock speeds and support their search for faster hash rate computations all the way,” says William Ko, president of the Company.

About Lotus Bio-Technology Corp:

Lotus Bio-Technology is a company actively seeking new opportunities to add shareholder value with strategic partnerships. The Company is currently headquartered in Kowloon, Hong Kong. It has an agreement with Coin Rig Solutions as of December 22, 2017, to allow the Company to enter the cryptocurrency industry, a half-trillion dollar marketplace.

Statements

Certain statements in this press release are forward-looking and involve a number of risks and uncertainties. Such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended.

Website: http://lotusbiotechnologies.com
Twitter: @LBTD_COIN_RIG

Forward-Looking Statements

Some information in this document constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements, such as the closing of the share exchange agreement. The words “want”, “willing”, “to lead”, “wishes”, “aspires”, “plan”, “forecast”, “anticipates”, “estimate”, “project”, “intend”, “expect”, “should”, “believe”, and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. All forward-looking statements attributable to Caduceus Software Systems Corp., herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Caduceus Software Systems Corp. disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

SOURCE: Lotus Bio-Technology Development Corp.

ReleaseID: 484986

NEW YORK, NY / ACCESSWIRE / December 27, 2017 / The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased RYB Education, Inc. (“RYB Education”) (NYSE: RYB) American Depositary Shares pursuant to the September 27, 2017 IPO or between September 27, 2017 and November 22, 2017.

Click here to learn about the case: http://www.wongesq.com/pslra-sb/ryb-education-inc?wire=2. There is no cost or obligation to you.

According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) RYB failed to establish safety policies to prevent sexual abuse from occurring at its schools; (ii) RYB’s failure to remedy problems within its system exposed children to harm and unreasonable risk of harm while in the Company’s care; and (iii) as a result of the foregoing, RYB securities traded at artificially inflated prices during the Class Period, and class members suffered significant losses and damages.

On November 24, 2017, media outlets announced that parents had accused an RYB Education nursery of drugging and abusing children. The same day, RYB Education issued a press release stating that a police investigation was ongoing. Then on November 27, 2017, RYB Education announced that one “teacher at the RYB-operated kindergarten in question was detained as a criminal suspect for maltreatment of children in the facility, and the police investigation is continuing.” RYB Education further stated that it would dismiss the accused teacher, effective immediately.

If you suffered a loss in RYB Education you have until January 26, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sbm/ryb-education-inc?wire=2.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 484984

NEW YORK, NY / ACCESSWIRE / December 27, 2017 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Alkermes plc (“Alkermes”) (NASDAQ: ALKS) between February 24, 2015 and November 3, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more information go to:

http://www.zlk.com/plsra-c/alkermes-plc?wire=2

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Alkermes had engaged in deceptive marketing campaigns to influence policymakers to use Vivitrol in addiction treatment programs over more scientifically proven and efficacious alternatives; (ii) the foregoing conduct, when disclosed, would subject Alkermes to heightened regulatory and legislative scrutiny; (iii) accordingly, the Company’s revenues derived from Vivitrol during the Class Period were unsustainable; and (iv) as a result of the foregoing, Alkermes shares traded at artificially inflated prices during the Class Period, and class members suffered significant losses and damages.

If you suffered a loss in Alkermes you have until January 22, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 484980

NEW YORK, NY / ACCESSWIRE / December 27, 2017 /Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Katanga Mining Limited (”Katanga” or the ”Company”) (OTC PINK: KATFF) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Katanga securities between February 11, 2016 through November 19, 2017, both dates inclusive (the ”Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/katff.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Katanga engaged in improper accounting practices; (2) there were material weaknesses in Katanga’s internal control over financial reporting; and (3) consequently, Katanga’s public statements were materially false and misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/katff or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Katanga you have until January 29, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 483228